Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osilodrostat Long-term Safety in Cushing's Syndrome (ISS-CA-2023)
NCT06131580Phase 4Unknown
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Oct 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of osilodrostat in Cushing's syndrome, sponsored by Centre hospitalier de l’Université de Montréal. Status: unknown.
02
Drugs
osilodrostat
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT06131580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131580.